business

Zealand Pharma (ZEAL) Shares Plunge 23% Following Safety Concerns Over Survodutide Data

06/08/2026, 07:35 PM business stock_drop healthcare
Zealand Pharma's shares fell sharply by 22.7% following concerns over the safety profile of its weight loss drug survodutide, which showed a high dropout rate due to gastrointestinal side effects in a late-stage study. This decline highlights the challenges the company faces in a competitive market dominated by established players like Novo Nordisk and Eli Lilly.
Novo Nordisk Eli Lilly

Novo Nordisk and Eli Lilly Compete for Dominance in the GLP-1 Pill Market Ahead of Medicare Coverage

Novo Nordisk and Eli Lilly are intensifying their competition in the GLP-1 pill market as they prepare for Medicare coverage, which could significantly increase access to their obesity treatments. Both companies are focusing on marketing strategies to appeal to seniors, who will soon be able to access these medications at a reduced cost.